Dr Michael Anstey is a Partner specialising in life science investments.
Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, market access, R&D strategy, and M&A.
Michael was also co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease.
Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses.
Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford.
Michael manages CIC's investments in Bicycle Therapeutics, Congenica, PredictImmune, Start Codon and Storm Therapeutics.